Novartis AG Retained Earnings (Accumulated Deficit) 2010-2024 | NVS

Novartis AG retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  • Novartis AG retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $42.564B, a 13.9% increase year-over-year.
  • Novartis AG retained earnings (accumulated deficit) for 2023 were $45.883B, a 21.63% decline from 2022.
  • Novartis AG retained earnings (accumulated deficit) for 2022 were $58.544B, a 12.36% decline from 2021.
  • Novartis AG retained earnings (accumulated deficit) for 2021 were $66.802B, a 19.85% increase from 2020.
Novartis AG Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $45,883
2022 $58,544
2021 $66,802
2020 $55,738
2019 $54,618
2018 $77,739
2017 $73,299
2016 $73,936
2015 $76,156
2014 $69,868
2013 $73,431
2012 $68,228
2011 $64,949
2010 $62,364
2009 $56,562
Novartis AG Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $42,564
2024-06-30 $40,965
2024-03-31 $38,899
2023-12-31 $45,883
2023-09-30 $37,371
2023-06-30 $51,057
2023-03-31 $51,253
2022-12-31 $58,544
2022-09-30 $60,000
2022-06-30 $62,095
2022-03-31 $60,699
2021-12-31 $66,802
2021-09-30 $55,917
2021-06-30 $53,194
2021-03-31 $49,670
2020-12-31 $55,738
2020-09-30 $53,615
2020-06-30 $52,936
2020-03-31 $50,035
2019-12-31 $54,618
2019-09-30 $51,668
2019-06-30 $50,557
2019-03-31 $46,348
2018-12-31 $77,739
2018-09-30 $77,063
2018-06-30 $75,934
2018-03-31 $70,222
2017-12-31 $73,299
2017-09-30
2017-06-30
2017-03-31
2016-12-31 $73,936
2016-09-30
2016-06-30
2016-03-31
2015-12-31 $76,156
2015-09-30
2015-06-30
2015-03-31
2014-12-31 $69,868
2014-09-30
2014-06-30
2014-03-31
2013-12-31 $73,431
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $68,228
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $64,949
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $62,364
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $56,562
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.584B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51